Market research
ATHE Alterity Therapeutics Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 85M
- P/E ratio
- Not available
- Analyst target
- 13.25
- Dividend yield
- Not available
- Beta
- -0.04
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US02155X2053
- Market cap
- 85M
- P/E ratio
- Not available
- Analyst target
- 13.25
- Dividend yield
- Not available
- Beta
- -0.04
About
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ATHE discussion.
5 years, 4 months ago
Alterity Therapeutics Limited is currently in a long term uptrend where the price is trading 30.1% above its 200 day moving average.
From a valuation standpoint, the stock is 44.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 737.7.
Alterity Therapeutics Limited's total revenue rose by 6564.3% to $942K since the same quarter in the previous year.
Its net income has increased by 24.1% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 182.0% to $-4M since the same quarter in the previous year.
Based on the above factors, Alterity Therapeutics Limited gets an overall score of 4/5.